• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Evolution and design of 'rate controlled' osmotic forms.

作者信息

Theeuwes F

出版信息

Curr Med Res Opin. 1983;8 Suppl 2:20-7. doi: 10.1185/03007998309109820.

DOI:10.1185/03007998309109820
PMID:6851622
Abstract

A new type of therapeutic system, the precision release osmotic form, has recently been developed. This new dosage form has been referred to in other publications as the gastro-intestinal therapeutic system (GITS). Its action is based on the principles of osmosis as a means of delivering precise amounts of drug over prolonged periods of time. The precision release form has evolved from a prototype design through a simplification and miniaturization process into the elementary osmotic pump, a simple, elegant delivery form that permits controlled drug release by osmosis. Sodium indomethacin trihydrate is the first drug to be incorporated into this precision release form ('Osmosin'). Comparisons with conventional drug forms have shown 'Osmosin' to produce more sustained and constant drug release profiles, thus aiming to improve the therapeutic applicability of a drug through a reduction in dose-related side-effects and allowing once-daily dosing.

摘要

相似文献

1
Evolution and design of 'rate controlled' osmotic forms.
Curr Med Res Opin. 1983;8 Suppl 2:20-7. doi: 10.1185/03007998309109820.
2
Biopharmaceutical evaluation of 'Osmosin'.
Curr Med Res Opin. 1983;8 Suppl 2:38-54. doi: 10.1185/03007998309109822.
3
The evolution of precision drug delivery.
Curr Med Res Opin. 1983;8 Suppl 2:28-37. doi: 10.1185/03007998309109821.
4
'Osmosin' (sodium indomethacin trihydrate) in the treatment of elderly patients with osteoarthritis.“奥斯莫辛”(吲哚美辛三水合钠)用于治疗老年骨关节炎患者。
Curr Med Res Opin. 1983;8 Suppl 2:72-82. doi: 10.1185/03007998309109826.
5
Innovations in drug delivery systems.药物递送系统的创新。
Curr Med Res Opin. 1983;8 Suppl 2:3-9. doi: 10.1185/03007998309109818.
6
Efficacy and tolerance of a novel precision-dose formulation of indomethacin: double-blind trials in rheumatoid arthritis and osteoarthritis.一种新型吲哚美辛精准剂量制剂的疗效与耐受性:类风湿性关节炎和骨关节炎的双盲试验
Curr Med Res Opin. 1983;8 Suppl 2:55-61. doi: 10.1185/03007998309109824.
7
'Osmosin' in general practice: preliminary report of a double-blind study in the treatment of osteoarthritis.全科医疗中的“奥索辛”:骨关节炎治疗双盲研究的初步报告
Curr Med Res Opin. 1983;8 Suppl 2:99-108. doi: 10.1185/03007998309109829.
8
Clinical evaluation of 'Osmosin' versus piroxicam.“Osmosin”与吡罗昔康的临床评估。
Curr Med Res Opin. 1983;8 Suppl 2:83-9. doi: 10.1185/03007998309109827.
9
Pharmacokinetics and pharmacodynamics of drug delivery.
Curr Med Res Opin. 1983;8 Suppl 2:10-9. doi: 10.1185/03007998309109819.
10
A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis.“奥索辛”、苯恶洛芬与安慰剂治疗骨关节炎的双盲对照研究。
Curr Med Res Opin. 1983;8 Suppl 2:90-8. doi: 10.1185/03007998309109828.

引用本文的文献

1
Development of an oral push-pull osmotic pump of fenofibrate-loaded mesoporous silica nanoparticles.载非诺贝特介孔二氧化硅纳米粒口服推拉渗透泵的研制。
Int J Nanomedicine. 2015 Mar 3;10:1691-701. doi: 10.2147/IJN.S76755. eCollection 2015.
2
Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study.一种缓释、不可变形口服剂型(OROS)的胃肠道安全性:一项回顾性研究
Drug Saf. 2002;25(14):1021-33. doi: 10.2165/00002018-200225140-00004.
3
Clinical and pharmacological study of a novel controlled release preparation of salbutamol.
沙丁胺醇新型控释制剂的临床与药理学研究
Br J Clin Pharmacol. 1990 May;29(5):578-80. doi: 10.1111/j.1365-2125.1990.tb03683.x.